These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 25658389)

  • 41. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.
    Larrubia JR; Moreno-Cubero E; Miquel J; Sanz-de-Villalobos E
    World J Gastroenterol; 2015 Mar; 21(12):3480-91. PubMed ID: 25834312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies.
    Ness E; Kowdley KV
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):145-58. PubMed ID: 25990619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.
    Majumdar A; Kitson MT; Roberts SK
    Drugs; 2015 May; 75(8):823-34. PubMed ID: 25943281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. REVIEW - Advancements in combination therapy of Hepatitis C virus.
    Jahangeer M; Ud Din NZ; Karim S; Hussain S; Ashiq M; Ali U; Ul Haq A; Munir N; Mahmood Z; Ghaffar A
    Pak J Pharm Sci; 2020 Sep; 33(5):2171-2178. PubMed ID: 33824126
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.
    Kanda T; Matsuoka S; Moriyama M
    Hepatol Int; 2018 Jul; 12(4):291-293. PubMed ID: 29992512
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of hepatitis C].
    Schneider MD; Kronenberger B; Zeuzem S; Sarrazin C
    Internist (Berl); 2015 Apr; 56(4):391-405. PubMed ID: 25762008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.
    Brown NA
    Expert Opin Investig Drugs; 2009 Jun; 18(6):709-25. PubMed ID: 19426125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
    Schiff L
    Clin Ther; 2015 May; 37(5):1092-112. PubMed ID: 25850880
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
    Lens S; Fernández I; Rodríguez-Tajes S; Hontangas V; Vergara M; Forné M; Calleja JL; Diago M; Llaneras J; Llerena S; Torras X; Sacristán B; Roget M; Fernández-Rodríguez CM; Navascués MC; Fuentes J; Sánchez-Ruano JJ; Simón MÁ; Sáez-Royuela F; Baliellas C; Morillas R; Forns X;
    Am J Gastroenterol; 2017 Sep; 112(9):1400-1409. PubMed ID: 28585554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are we nearing the end in the fight against hepatitis C?
    Chua JV; Kottilil S
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):499-500. PubMed ID: 28335650
    [No Abstract]   [Full Text] [Related]  

  • 51. New treatments for chronic hepatitis C: an overview for paediatricians.
    Serranti D; Indolfi G; Resti M
    World J Gastroenterol; 2014 Nov; 20(43):15965-74. PubMed ID: 25473150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
    Miller MH; Agarwal K; Austin A; Brown A; Barclay ST; Dundas P; Dusheiko GM; Foster GR; Fox R; Hayes PC; Leen C; Millson C; Ryder SD; Tait J; Ustianowski A; Dillon JF; ; ; ; ; ;
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1363-75. PubMed ID: 24754233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genotype 1 hepatitis C virus and the pharmacist's role in treatment.
    Sebhatu P; Martin MT
    Am J Health Syst Pharm; 2016 Jun; 73(11):764-74. PubMed ID: 27126832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review.
    Fehily SR; Papaluca T; Thompson AJ
    Semin Liver Dis; 2019 Jul; 39(3):341-353. PubMed ID: 31041785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.
    Alqahtani S; Sulkowski M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):825-43. PubMed ID: 26600222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Viral resistance in HCV infection.
    Ceccherini-Silberstein F; Cento V; Di Maio VC; Perno CF; Craxì A
    Curr Opin Virol; 2018 Oct; 32():115-127. PubMed ID: 30439589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.
    Brzdęk M; Zarębska-Michaluk D; Invernizzi F; Cilla M; Dobrowolska K; Flisiak R
    World J Gastroenterol; 2023 Feb; 29(6):949-966. PubMed ID: 36844142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Direct Acting Antiviral Agents for the Treatment of Hepatitis C: 2016 and Beyond.
    Umar M; Akhter TS
    J Coll Physicians Surg Pak; 2016 Oct; 26(10):843-850. PubMed ID: 27806815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reinventing HCV Treatment: Past and Future Perspectives.
    Carter W; Connelly S; Struble K
    J Clin Pharmacol; 2017 Mar; 57(3):287-296. PubMed ID: 27654843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.